1. Phylogeny  
   Casein kinase II subunit alpha (CK2α1), encoded by the CSNK2A1 gene (UniProt ID: P68400), is an evolutionarily conserved catalytic subunit of the CK2 holoenzyme that is present in all eukaryotic cells and can be traced back to early eukaryotic ancestors (battistutta2009proteinkinaseck2 pages 4-5, bischoff2011structureofthe pages 10-11). CK2α1 is classified within the CMGC group of kinases, which includes cyclin-dependent kinases, mitogen-activated protein kinases, glycogen synthase kinase-3, and CDK-like kinases, underscoring its deep evolutionary separation from other kinase families such as the AGC kinases (cozza2010howdruggableis pages 1-3). Orthologs of CK2α1 have been identified in species ranging from yeast to humans, with its catalytic domain showing high sequence conservation and remarkable structural similarity across eukaryotes (dobrowolska2004ck2aprotein pages 1-2, bischoff2011structureofthe pages 10-11). Moreover, phylogenetic studies have demonstrated that the CK2 complex represents an ancient regulatory system, forming an integral part of the cellular regulatory core that has been maintained through evolution (cozza2010howdruggableis pages 1-3). Detailed comparative analyses have revealed that not only is CK2α1 conserved in terms of its primary amino acid sequence, but its functional motifs — including key ATP‐binding and catalytic residues — are preserved across species, further emphasizing its central role in eukaryotic cellular processes (issinger2009proteinkinaseck2 pages 1-6). The evolutionary relationships of CK2α1 with other kinases in the human kinome have placed it on a distinct branch that diverged early from kinases regulated by second‐messenger systems, and its constitutive activity supports its role as a central regulatory node (battistutta2009proteinkinaseck2 pages 4-5). Collectively, these data underscore that CK2α1 is embedded in an evolutionary core of protein kinases vital for cell survival, proliferation, and the regulation of diverse signaling pathways (cozza2010howdruggableis pages 1-3).
2. Reaction Catalyzed  
   CK2α1 catalyzes a phosphotransfer reaction in which the γ‐phosphate group from ATP is transferred to the hydroxyl side chain of serine or threonine residues on protein substrates, yielding ADP and a phosphorylated protein product along with the liberation of a proton (cozza2010howdruggableis pages 1-3, bischoff2011structureofthe pages 11-12). This nucleotide-dependent reaction is central to the function of CK2α1 and underpins its ability to modulate the activities of a multitude of protein substrates that are critical for numerous cellular processes (bruserud2023caseinkinase2 pages 1-2). Because the enzyme is constitutively active, the catalytic transfer occurs continuously and is not dependent on additional activation events, ensuring that CK2-mediated phosphorylation remains a constant modulatory influence within the cell (cozza2013kinaseck2inhibition pages 1-1).
3. Cofactor Requirements  
   The enzymatic activity of CK2α1 relies on the presence of divalent metal ions, with magnesium (Mg²⁺) being essential to its catalytic mechanism (bischoff2011structureofthe pages 11-12). Mg²⁺ functions as a cofactor by coordinating the phosphates of ATP within the active site, thereby facilitating the proper orientation of the nucleotide for the phosphotransfer reaction to occur (ermakova2003crystalstructureof pages 1-3). In addition to Mg²⁺, under certain experimental conditions, manganese (Mn²⁺) may also support CK2 activity; however, Mg²⁺ is the physiologically relevant cofactor that ensures high efficiency and fidelity in the phosphorylation process (cozza2010howdruggableis pages 1-3).
4. Substrate Specificity  
   CK2α1 exhibits a striking substrate preference for serine and threonine residues that are embedded within acidic amino acid contexts, typically favoring substrates that contain negatively charged residues such as aspartate (Asp) or glutamate (Glu) immediately C-terminal to the phosphoacceptor (battistutta2009proteinkinaseck2 pages 4-5, bischoff2011structureofthe pages 11-12). The minimal consensus sequence recognized by CK2 typically conforms to the motif Ser/Thr-X-X-Asp/Glu, where other acidic residues may further enhance binding and phosphorylation efficiency (bischoff2011structureofthe pages 11-12). Although CK2α1 is primarily characterized as a serine/threonine kinase, it also exhibits dual-specificity activity under certain conditions by phosphorylating tyrosine residues at a much lower efficiency, thereby broadening its substrate repertoire (issinger2009proteinkinaseck2 pages 6-9). The enzyme’s broad substrate specificity is augmented by the interactions mediated by the regulatory CK2β subunits when the enzyme forms a holoenzyme complex, which can subtly modulate its substrate selectivity and enhance phosphorylation rates for specific target proteins (battistutta2009proteinkinaseck2 pages 4-5).
5. Structure  
   CK2α1 possesses a canonical bilobal kinase structure that is highly characteristic of the eukaryotic protein kinase superfamily (ermakova2003crystalstructureof pages 1-3, bischoff2011structureofthe pages 10-11). The N-terminal lobe of CK2α1 is composed primarily of β-strands and a short α-helix and functions predominantly in the binding of ATP, while the larger C-terminal lobe is mainly α-helical and provides the structural framework for substrate recognition and catalysis (cozza2010howdruggableis pages 3-6). Key elements of the active site include the glycine-rich loop (P-loop), which is slightly divergent in CK2 compared to other kinases due to unique substitutions that contribute to its acidic substrate preference (cozza2010howdruggableis pages 3-6, cozza2013kinaseck2inhibition pages 3-4). Conserved catalytic residues such as Lys68, which is critical for anchoring the phosphate groups of ATP, Glu81, which forms a salt bridge with Lys68, Asp156, serving as the catalytic base, and additional residues involved in metal ion coordination, are strictly conserved in CK2α1 and are essential for its catalytic function (litchfield2003proteinkinaseck2 pages 1-2, ermakova2003crystalstructureof pages 1-3). Structural studies have revealed that CK2α1 maintains an “always active” conformation due to the stabilization of its activation segment and helix αC by interactions from the N-terminal region, which obviates the requirement for regulatory activation loop phosphorylation seen in many other kinases (cozza2010howdruggableis pages 1-3, cozza2016caseinkinasesas pages 1-3). An additional unique feature of CK2α1 is its ability to accommodate both ATP and GTP as phosphate donors—a property that results from distinctive hydrogen-bonding patterns and the inherent plasticity of its nucleotide-binding pocket (cozza2013kinaseck2inhibition pages 1-1, cozza2010howdruggableis pages 3-6). When assembled into the tetrameric holoenzyme, two CK2α1 molecules interact indirectly via a dimer of regulatory β subunits, which not only provide structural stability but also critically influence substrate docking and overall catalytic efficiency (battistutta2009proteinkinaseck2 pages 4-5, cozza2010howdruggableis pages 6-9).
6. Regulation  
   CK2α1 is unique among protein kinases because it exhibits constitutive activity and does not require the phosphorylation of its activation loop for full enzymatic activity (dobrowolska2004ck2aprotein pages 1-2, ermakova2003crystalstructureof pages 1-3). Instead, regulation of CK2α1 is predominantly achieved through its assembly with regulatory β subunits into a heterotetrameric holoenzyme, a process that modulates both substrate specificity and catalytic stability (bischoff2011structureofthe pages 11-12, issinger2009proteinkinaseck2 pages 1-6). In the holoenzyme, the CK2β subunits act as scaffolds that not only stabilize the complex but also contribute to the precise docking of substrates, as well as providing additional sites for potential regulatory protein interactions (cozza2010howdruggableis pages 6-9, cozza2016caseinkinasesas pages 16-16). Although CK2α1 is inherently active, autophosphorylation events and phosphorylation of specific residues—especially in the context of cellular stress or during the cell cycle—have been observed to fine-tune its activity and select discrete signaling outputs (litchfield2003proteinkinaseck2 pages 2-3, issinger2009proteinkinaseck2 pages 9-12). Moreover, binding of small molecules and regulatory peptides, as well as changes in subcellular localization, are additional layers through which CK2α1 activity is modulated; for instance, interactions with polybasic proteins and the anchoring of the holoenzyme to distinct subcellular compartments can affect its substrate accessibility (cozza2010howdruggableis pages 31-33, cozza2013kinaseck2inhibition pages 3-4). In summary, rather than relying on traditional on/off switches, the regulation of CK2α1 is achieved by dynamic holoenzyme assembly, post-translational modifications, and interaction with a diverse set of regulatory proteins (dobrowolska2004ck2aprotein pages 1-2, litchfield2003proteinkinaseck2 pages 5-6).
7. Function  
   CK2α1 serves as the catalytic core of a serine/threonine-protein kinase complex with extraordinary substrate diversity, phosphorylating a large number of proteins involved in numerous critical cellular processes (bruserud2023caseinkinase2 pages 1-2, battistutta2009proteinkinaseck2 pages 4-5). Its substrates include regulators of cell cycle progression, transcription factors, DNA repair proteins, and components of signaling cascades such as the PI3K–Akt–mTOR pathway, thereby positioning CK2α1 as an essential mediator of cell growth, proliferation, and survival (bischoff2011structureofthe pages 11-12, cozza2016caseinkinasesas pages 16-16). During mitosis, CK2α1 functions as part of the p53/TP53-dependent spindle assembly checkpoint (SAC), where its kinase activity is crucial for maintaining cyclin-B–CDK1 activity and enforcing G2 arrest in response to spindle damage (battistutta2009proteinkinaseck2 pages 4-5, litchfield2003proteinkinaseck2 pages 5-6). Additionally, CK2α1-mediated phosphorylation is implicated in apoptotic regulation, with its activity often promoting cell survival by phosphorylating pro-apoptotic proteins and thereby inhibiting apoptotic pathways (gowda2017caseinkinaseii pages 1-3, issinger2009proteinkinaseck2 pages 12-16). In the context of transcriptional regulation, CK2α1 phosphorylates a variety of transcription factors and components of the transcriptional machinery, affecting gene expression programs that govern cellular differentiation and response to stress (cozza2010howdruggableis pages 31-33, bischoff2011structureofthe pages 11-12). Furthermore, elevated levels or hyperactivation of CK2α1 have been observed in multiple cancer types, where the kinase drives oncogenic processes including increased proliferation, resistance to apoptosis, angiogenesis, and metastasis (borgo2021proteinkinaseck2 pages 14-14, cozza2013kinaseck2inhibition pages 17-18). Through its extensive substrate portfolio, CK2α1 integrates various signaling cues to coordinate a balanced cellular response, thus acting as a regulatory node that is central to maintaining cellular homeostasis (bruserud2023caseinkinase2 pages 1-2, cozza2016caseinkinasesas pages 16-17).
8. Other Comments  
   A number of small-molecule inhibitors have been developed to target CK2α1, among which ATP-competitive inhibitors like CX-4945 have shown significant promise in preclinical cancer models and are currently under clinical evaluation for their anticancer efficacy (cozza2013kinaseck2inhibition pages 17-18, borgo2021proteinkinaseck2 pages 16-17). In addition to oncological applications, CK2α1 has been implicated in viral infections and neurodegenerative disorders, where its dysregulation contributes to aberrant phosphorylation patterns and pathological protein aggregation (bruserud2023caseinkinase2 pages 1-2, perez2011proteinkinasesck1 pages 1-3). Notably, the constitutive activity of CK2α1 and its role as a signal integrator make it an attractive target for therapeutic intervention, as modulating its activity may correct the downstream effects on cell cycle progression, apoptosis, and transcription that are observed in various disease states (cozza2010howdruggableis pages 37-39, issinger2009proteinkinaseck2 pages 31-37). Furthermore, several allosteric inhibitors and substrate-competitive peptides have emerged as alternative strategies to overcome selectivity issues posed by the highly conserved ATP-binding pocket (prudent2010structurebaseddiscoveryof pages 6-6, choi2024caseinkinase2 pages 23-25). Dysregulation of CK2α1 through overexpression or mutations is also associated with specific developmental disorders and immune dysfunctions, further highlighting the need for precise modulation of its kinase activity in clinical settings (gowda2017caseinkinaseii pages 1-3, venerando2022editorialcaseinkinases pages 1-3).
9. References
10. Battistutta, R. “Protein kinase CK2 in health and disease.” Cellular and Molecular Life Sciences, vol. 66, Apr 2009, pp. 1868-1889. (battistutta2009proteinkinaseck2 pages 4-5)
11. Bischoff, N., Olsen, B., Raaf, J., Bretner, M., Issinger, O., and Niefind, K. “Structure of the human protein kinase CK2 catalytic subunit CK2α′ and interaction thermodynamics with the regulatory subunit CK2β.” Journal of Molecular Biology, vol. 407, Mar 2011, pp. 1-12. (bischoff2011structureofthe pages 10-11, bischoff2011structureofthe pages 11-12)
12. Bruserud, Ø., Reikvam, H. “Casein kinase 2 (CK2): a possible therapeutic target in acute myeloid leukemia.” Cancers, vol. 15, Jul 2023, Article 3711. (bruserud2023caseinkinase2 pages 1-2)
13. Cozza, G., Bortolato, A., Moro, S. “How druggable is protein kinase CK2?” Medicinal Research Reviews, vol. 20, May 2010, pp. 1-37. (cozza2010howdruggableis pages 1-3, cozza2010howdruggableis pages 3-6, cozza2010howdruggableis pages 31-33, cozza2010howdruggableis pages 37-39)
14. Cozza, G., Pinna, L., Moro, S. “Kinase CK2 inhibition: an update.” Current Medicinal Chemistry, vol. 20, Jan 2013, pp. 1-4, 17-18. (cozza2013kinaseck2inhibition pages 1-1, cozza2013kinaseck2inhibition pages 1-3, cozza2013kinaseck2inhibition pages 3-4, cozza2013kinaseck2inhibition pages 17-18)
15. Cozza, G., Pinna, L. “Casein kinases as potential therapeutic targets.” Expert Opinion on Therapeutic Targets, vol. 20, Mar 2016, pp. 319-340. (cozza2016caseinkinasesas pages 1-3, cozza2016caseinkinasesas pages 16-16, cozza2016caseinkinasesas pages 20-21, cozza2016caseinkinasesas pages 3-4, cozza2016caseinkinasesas pages 16-17)
16. Dobrowolska, G., Lozeman, F.J., Li, D., Krebs, E.G. “CK2, a protein kinase of the next millennium.” Molecular and Cellular Biochemistry, vol. 191, Jan 2004, pp. 3-12. (dobrowolska2004ck2aprotein pages 1-2, dobrowolska2004ck2aprotein pages 9-10)
17. Ermakova, I., Boldyreff, B., Issinger, O., Niefind, K. “Crystal structure of a C-terminal deletion mutant of human protein kinase CK2 catalytic subunit.” Journal of Molecular Biology, vol. 330, Jul 2003, pp. 925-934. (ermakova2003crystalstructureof pages 1-3, ermakova2003crystalstructureof pages 8-9, ermakova2003crystalstructureof pages 9-10)
18. Guerra, B., Issinger, O.-G. “Protein kinase CK2 and its role in cellular proliferation, development and pathology.” Electrophoresis, vol. 20, Feb 1999, pp. 391-408. (guerra1999proteinkinaseck2 pages 1-2)
19. Guerra, B., Issinger, O.-G. “Protein kinase CK2 in human diseases.” Current Medicinal Chemistry, vol. 15, Aug 2008, pp. 1870-1886. (guerra2008proteinkinaseck2 pages 1-2)
20. Issinger, O.G., Niefind, K., Raaf, J. “Protein kinase CK2 in health and disease.” Cellular and Molecular Life Sciences, vol. 66, Apr 2009, pp. 1800-1816. (issinger2009proteinkinaseck2 pages 1-6, issinger2009proteinkinaseck2 pages 31-37, issinger2009proteinkinaseck2 pages 6-9, issinger2009proteinkinaseck2 pages 9-12)
21. Litchfield, D.W. “Protein kinase CK2: structure, regulation and role in cellular decisions of life and death.” Biochemical Journal, vol. 369, Jan 2003, pp. 1-15. (litchfield2003proteinkinaseck2 pages 1-2, litchfield2003proteinkinaseck2 pages 11-11, litchfield2003proteinkinaseck2 pages 2-3, litchfield2003proteinkinaseck2 pages 5-6)
22. Montenarh, M., Götz, C. “Protein kinase CK2 and ion channels (review).” Biomedical Reports, vol. 13, Sep 2020, pp. 1-1. (montenarh2020proteinkinaseck2 pages 6-7)
23. Olsen, B.B., Guerra, B., Niefind, K., Issinger, O.-G. “Structural basis of the constitutive activity of protein kinase CK2.” Methods in Enzymology, vol. 484, Jan 2010, pp. 515-529. (olsen2010structuralbasisof pages 15-15)
24. Perez, D.I., Gil, C., Martinez, A. “Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases.” Medicinal Research Reviews, Nov 2011, pp. 21-23. (perez2011proteinkinasesck1 pages 21-23, perez2011proteinkinasesck1 pages 1-3)
25. Rekha, N., Srinivasan, N. “Structural basis of regulation and substrate specificity of protein kinase CK2 deduced from the modeling of protein-protein interactions.” BMC Structural Biology, vol. 3, May 2003, Article 4. (rekha2003structuralbasisof pages 1-2)
26. Venerando, A., Bustos, V.H., Pinna, L.A., Cozza, G. “Editorial: casein kinases in human diseases.” Frontiers in Molecular Biosciences, Dec 2022, Article 1094922. (venerando2022editorialcaseinkinases pages 1-3, venerando2022editorialcaseinkinases pages 3-4)
27. Villavicencio-Diaz, T.N., Rabalski, A., Litchfield, D. “Protein kinase CK2: intricate relationships within regulatory cellular networks.” Pharmaceuticals, vol. 10, Mar 2017, Article 27. (villavicenciodiaz2017proteinkinaseck2 pages 1-3, villavicenciodiaz2017proteinkinaseck2 pages 8-10)
28. Werner, C., Eimermacher, S., Harasimowicz, H., Fischer, D., Pietsch, M., Niefind, K. “A CK2α′ mutant indicating why CK2α and CK2α′, the isoforms of the catalytic subunit of human protein kinase CK2, deviate in affinity to CK2β.” Biological Chemistry, Apr 2025. (werner2025ack2α′mutant pages 15-15)
29. Cao, J.Y., Shire, K., Landry, C., Gish, G.D., Pawson, T., Frappier, L. “Identification of a novel protein interaction motif in the regulatory subunit of casein kinase 2.” Molecular and Cellular Biology, vol. 34, Jan 2014, pp. 246-258. (cao2014identificationofa pages 13-13)
30. Choi, Y., Yu, S.-R., Lee, Y., Na, A.-Y., Lee, S., Heitman, J., Seo, R., Lee, H.-S., Lee, J.-S., Bahn, Y.-S. “Casein kinase 2 complex: a central regulator of multiple pathobiological signaling pathways in Cryptococcus neoformans.” mBio, Feb 2024. (choi2024caseinkinase2 pages 23-25)
31. Prudent, R., Sautel, C.F., Cochet, C. “Structure-based discovery of small molecules targeting different surfaces of protein-kinase CK2.” Biochimica et Biophysica Acta (BBA) – Proteins and Proteomics, vol. 1804, Mar 2010, pp. 493-498. (prudent2010structurebaseddiscoveryof pages 6-6)

References

1. (battistutta2009proteinkinaseck2 pages 4-5): R Battistutta. Protein kinase ck2 in health and disease. Cellular and Molecular Life Sciences, 66:1868-1889, Apr 2009. URL: https://doi.org/10.1007/s00018-009-9155-x, doi:10.1007/s00018-009-9155-x. This article has 115 citations and is from a domain leading peer-reviewed journal.
2. (bischoff2011structureofthe pages 10-11): N. Bischoff, B. Olsen, J. Raaf, M. Bretner, O. Issinger, and K. Niefind. Structure of the human protein kinase ck2 catalytic subunit ck2α’ and interaction thermodynamics with the regulatory subunit ck2β. Journal of molecular biology, 407 1:1-12, Mar 2011. URL: https://doi.org/10.1016/j.jmb.2011.01.020, doi:10.1016/j.jmb.2011.01.020. This article has 62 citations and is from a domain leading peer-reviewed journal.
3. (bischoff2011structureofthe pages 11-12): N. Bischoff, B. Olsen, J. Raaf, M. Bretner, O. Issinger, and K. Niefind. Structure of the human protein kinase ck2 catalytic subunit ck2α’ and interaction thermodynamics with the regulatory subunit ck2β. Journal of molecular biology, 407 1:1-12, Mar 2011. URL: https://doi.org/10.1016/j.jmb.2011.01.020, doi:10.1016/j.jmb.2011.01.020. This article has 62 citations and is from a domain leading peer-reviewed journal.
4. (bruserud2023caseinkinase2 pages 1-2): Øystein Bruserud and Håkon Reikvam. Casein kinase 2 (ck2): a possible therapeutic target in acute myeloid leukemia. Cancers, 15:3711, Jul 2023. URL: https://doi.org/10.3390/cancers15143711, doi:10.3390/cancers15143711. This article has 13 citations and is from a peer-reviewed journal.
5. (cozza2010howdruggableis pages 1-3): Giorgio Cozza, Andrea Bortolato, and Stefano Moro. How druggable is protein kinase ck2? Medicinal Research Reviews, May 2010. URL: https://doi.org/10.1002/med.20164, doi:10.1002/med.20164. This article has 85 citations and is from a domain leading peer-reviewed journal.
6. (cozza2010howdruggableis pages 3-6): Giorgio Cozza, Andrea Bortolato, and Stefano Moro. How druggable is protein kinase ck2? Medicinal Research Reviews, May 2010. URL: https://doi.org/10.1002/med.20164, doi:10.1002/med.20164. This article has 85 citations and is from a domain leading peer-reviewed journal.
7. (cozza2010howdruggableis pages 31-33): Giorgio Cozza, Andrea Bortolato, and Stefano Moro. How druggable is protein kinase ck2? Medicinal Research Reviews, May 2010. URL: https://doi.org/10.1002/med.20164, doi:10.1002/med.20164. This article has 85 citations and is from a domain leading peer-reviewed journal.
8. (cozza2010howdruggableis pages 6-9): Giorgio Cozza, Andrea Bortolato, and Stefano Moro. How druggable is protein kinase ck2? Medicinal Research Reviews, May 2010. URL: https://doi.org/10.1002/med.20164, doi:10.1002/med.20164. This article has 85 citations and is from a domain leading peer-reviewed journal.
9. (cozza2013kinaseck2inhibition pages 1-1): G. Cozza, L. Pinna, and S. Moro. Kinase ck2 inhibition: an update. Current Medicinal Chemistry, 20:671-693, Jan 2013. URL: https://doi.org/10.2174/092986713804999312, doi:10.2174/092986713804999312. This article has 110 citations and is from a peer-reviewed journal.
10. (cozza2013kinaseck2inhibition pages 1-3): G. Cozza, L. Pinna, and S. Moro. Kinase ck2 inhibition: an update. Current Medicinal Chemistry, 20:671-693, Jan 2013. URL: https://doi.org/10.2174/092986713804999312, doi:10.2174/092986713804999312. This article has 110 citations and is from a peer-reviewed journal.
11. (cozza2013kinaseck2inhibition pages 3-4): G. Cozza, L. Pinna, and S. Moro. Kinase ck2 inhibition: an update. Current Medicinal Chemistry, 20:671-693, Jan 2013. URL: https://doi.org/10.2174/092986713804999312, doi:10.2174/092986713804999312. This article has 110 citations and is from a peer-reviewed journal.
12. (cozza2016caseinkinasesas pages 1-3): Giorgio Cozza and Lorenzo A Pinna. Casein kinases as potential therapeutic targets. Expert Opinion on Therapeutic Targets, 20:319-340, Mar 2016. URL: https://doi.org/10.1517/14728222.2016.1091883, doi:10.1517/14728222.2016.1091883. This article has 103 citations and is from a peer-reviewed journal.
13. (cozza2016caseinkinasesas pages 16-16): Giorgio Cozza and Lorenzo A Pinna. Casein kinases as potential therapeutic targets. Expert Opinion on Therapeutic Targets, 20:319-340, Mar 2016. URL: https://doi.org/10.1517/14728222.2016.1091883, doi:10.1517/14728222.2016.1091883. This article has 103 citations and is from a peer-reviewed journal.
14. (cozza2016caseinkinasesas pages 20-21): Giorgio Cozza and Lorenzo A Pinna. Casein kinases as potential therapeutic targets. Expert Opinion on Therapeutic Targets, 20:319-340, Mar 2016. URL: https://doi.org/10.1517/14728222.2016.1091883, doi:10.1517/14728222.2016.1091883. This article has 103 citations and is from a peer-reviewed journal.
15. (cozza2016caseinkinasesas pages 3-4): Giorgio Cozza and Lorenzo A Pinna. Casein kinases as potential therapeutic targets. Expert Opinion on Therapeutic Targets, 20:319-340, Mar 2016. URL: https://doi.org/10.1517/14728222.2016.1091883, doi:10.1517/14728222.2016.1091883. This article has 103 citations and is from a peer-reviewed journal.
16. (dobrowolska2004ck2aprotein pages 1-2): Grazyna Dobrowolska, Fred J. Lozeman, Dongxia Li, and Edwin G. Krebs. Ck2, a protein kinase of the next millennium. Molecular and Cellular Biochemistry, 191:3-12, Jan 2004. URL: https://doi.org/10.1023/a:1006882910351, doi:10.1023/a:1006882910351. This article has 66 citations and is from a peer-reviewed journal.
17. (dobrowolska2004ck2aprotein pages 9-10): Grazyna Dobrowolska, Fred J. Lozeman, Dongxia Li, and Edwin G. Krebs. Ck2, a protein kinase of the next millennium. Molecular and Cellular Biochemistry, 191:3-12, Jan 2004. URL: https://doi.org/10.1023/a:1006882910351, doi:10.1023/a:1006882910351. This article has 66 citations and is from a peer-reviewed journal.
18. (ermakova2003crystalstructureof pages 1-3): I. Ermakova, B. Boldyreff, O. Issinger, and K. Niefind. Crystal structure of a c-terminal deletion mutant of human protein kinase ck2 catalytic subunit. Journal of molecular biology, 330 5:925-34, Jul 2003. URL: https://doi.org/10.1016/s0022-2836(03)00638-7, doi:10.1016/s0022-2836(03)00638-7. This article has 90 citations and is from a domain leading peer-reviewed journal.
19. (ermakova2003crystalstructureof pages 8-9): I. Ermakova, B. Boldyreff, O. Issinger, and K. Niefind. Crystal structure of a c-terminal deletion mutant of human protein kinase ck2 catalytic subunit. Journal of molecular biology, 330 5:925-34, Jul 2003. URL: https://doi.org/10.1016/s0022-2836(03)00638-7, doi:10.1016/s0022-2836(03)00638-7. This article has 90 citations and is from a domain leading peer-reviewed journal.
20. (ermakova2003crystalstructureof pages 9-10): I. Ermakova, B. Boldyreff, O. Issinger, and K. Niefind. Crystal structure of a c-terminal deletion mutant of human protein kinase ck2 catalytic subunit. Journal of molecular biology, 330 5:925-34, Jul 2003. URL: https://doi.org/10.1016/s0022-2836(03)00638-7, doi:10.1016/s0022-2836(03)00638-7. This article has 90 citations and is from a domain leading peer-reviewed journal.
21. (guerra1999proteinkinaseck2 pages 1-2): Barbara Guerra and Olaf-Georg Issinger. Protein kinase ck2 and its role in cellular proliferation, development and pathology. Electrophoresis, 20:391-408, Feb 1999. URL: https://doi.org/10.1002/(sici)1522-2683(19990201)20:2<391::aid-elps391>3.0.co;2-n, doi:10.1002/(sici)1522-2683(19990201)20:2<391::aid-elps391>3.0.co;2-n. This article has 527 citations and is from a peer-reviewed journal.
22. (guerra2008proteinkinaseck2 pages 1-2): Barbara Guerra and Olaf-Georg Issinger. Protein kinase ck2 in human diseases. Current Medicinal Chemistry, 15:1870-1886, Aug 2008. URL: https://doi.org/10.2174/092986708785132933, doi:10.2174/092986708785132933. This article has 296 citations and is from a peer-reviewed journal.
23. (issinger2009proteinkinaseck2 pages 1-6): OG Issinger K Niefind, J Raaf. Protein kinase ck2 in health and disease. Cellular and Molecular Life Sciences, 66:1800-1816, Apr 2009. URL: https://doi.org/10.1007/s00018-009-9149-8, doi:10.1007/s00018-009-9149-8. This article has 134 citations and is from a domain leading peer-reviewed journal.
24. (issinger2009proteinkinaseck2 pages 31-37): OG Issinger K Niefind, J Raaf. Protein kinase ck2 in health and disease. Cellular and Molecular Life Sciences, 66:1800-1816, Apr 2009. URL: https://doi.org/10.1007/s00018-009-9149-8, doi:10.1007/s00018-009-9149-8. This article has 134 citations and is from a domain leading peer-reviewed journal.
25. (issinger2009proteinkinaseck2 pages 6-9): OG Issinger K Niefind, J Raaf. Protein kinase ck2 in health and disease. Cellular and Molecular Life Sciences, 66:1800-1816, Apr 2009. URL: https://doi.org/10.1007/s00018-009-9149-8, doi:10.1007/s00018-009-9149-8. This article has 134 citations and is from a domain leading peer-reviewed journal.
26. (issinger2009proteinkinaseck2 pages 9-12): OG Issinger K Niefind, J Raaf. Protein kinase ck2 in health and disease. Cellular and Molecular Life Sciences, 66:1800-1816, Apr 2009. URL: https://doi.org/10.1007/s00018-009-9149-8, doi:10.1007/s00018-009-9149-8. This article has 134 citations and is from a domain leading peer-reviewed journal.
27. (litchfield2003proteinkinaseck2 pages 1-2): David W. LITCHFIELD. Protein kinase ck2: structure, regulation and role in cellular decisions of life and death. Biochemical Journal, 369:1-15, Jan 2003. URL: https://doi.org/10.1042/bj20021469, doi:10.1042/bj20021469. This article has 1572 citations and is from a domain leading peer-reviewed journal.
28. (litchfield2003proteinkinaseck2 pages 11-11): David W. LITCHFIELD. Protein kinase ck2: structure, regulation and role in cellular decisions of life and death. Biochemical Journal, 369:1-15, Jan 2003. URL: https://doi.org/10.1042/bj20021469, doi:10.1042/bj20021469. This article has 1572 citations and is from a domain leading peer-reviewed journal.
29. (montenarh2020proteinkinaseck2 pages 6-7): Mathias Montenarh and Claudia Götz. Protein kinase ck2 and ion channels (review). Biomedical Reports, 13:1-1, Sep 2020. URL: https://doi.org/10.3892/br.2020.1362, doi:10.3892/br.2020.1362. This article has 28 citations and is from a peer-reviewed journal.
30. (olsen2010structuralbasisof pages 15-15): Birgitte B. Olsen, Barbara Guerra, Karsten Niefind, and Olaf-Georg Issinger. Structural basis of the constitutive activity of protein kinase ck2. Methods in Enzymology, 484:515-529, Jan 2010. URL: https://doi.org/10.1016/b978-0-12-381298-8.00025-3, doi:10.1016/b978-0-12-381298-8.00025-3. This article has 25 citations and is from a peer-reviewed journal.
31. (perez2011proteinkinasesck1 pages 21-23): Daniel I. Perez, Carmen Gil, and Ana Martinez. Protein kinases ck1 and ck2 as new targets for neurodegenerative diseases. Medicinal Research Reviews, Nov 2011. URL: https://doi.org/10.1002/med.20207, doi:10.1002/med.20207. This article has 199 citations and is from a domain leading peer-reviewed journal.
32. (rekha2003structuralbasisof pages 1-2): Nambudiry Rekha and N Srinivasan. Structural basis of regulation and substrate specificity of protein kinase ck2 deduced from the modeling of protein-protein interactions. BMC Structural Biology, 3:4-4, May 2003. URL: https://doi.org/10.1186/1472-6807-3-4, doi:10.1186/1472-6807-3-4. This article has 27 citations and is from a peer-reviewed journal.
33. (venerando2022editorialcaseinkinases pages 3-4): Andrea Venerando, Victor H. Bustos, Lorenzo A. Pinna, and Giorgio Cozza. Editorial: casein kinases in human diseases. Frontiers in Molecular Biosciences, Dec 2022. URL: https://doi.org/10.3389/fmolb.2022.1094922, doi:10.3389/fmolb.2022.1094922. This article has 2 citations and is from a peer-reviewed journal.
34. (villavicenciodiaz2017proteinkinaseck2 pages 1-3): Teresa Nuñez de Villavicencio-Diaz, Adam Rabalski, and David Litchfield. Protein kinase ck2: intricate relationships within regulatory cellular networks. Pharmaceuticals, 10:27, Mar 2017. URL: https://doi.org/10.3390/ph10010027, doi:10.3390/ph10010027. This article has 109 citations and is from a peer-reviewed journal.
35. (villavicenciodiaz2017proteinkinaseck2 pages 8-10): Teresa Nuñez de Villavicencio-Diaz, Adam Rabalski, and David Litchfield. Protein kinase ck2: intricate relationships within regulatory cellular networks. Pharmaceuticals, 10:27, Mar 2017. URL: https://doi.org/10.3390/ph10010027, doi:10.3390/ph10010027. This article has 109 citations and is from a peer-reviewed journal.
36. (werner2025ack2α′mutant pages 15-15): Christian Werner, Sophia Eimermacher, Hugo Harasimowicz, Dietmar Fischer, Markus Pietsch, and Karsten Niefind. A ck2α′ mutant indicating why ck2α and ck2α′, the isoforms of the catalytic subunit of human protein kinase ck2, deviate in affinity to ck2β. Biological Chemistry, Apr 2025. URL: https://doi.org/10.1515/hsz-2024-0157, doi:10.1515/hsz-2024-0157. This article has 0 citations and is from a peer-reviewed journal.
37. (borgo2021proteinkinaseck2 pages 14-14): Christian Borgo, Claudio D’Amore, Stefania Sarno, Mauro Salvi, and Maria Ruzzene. Protein kinase ck2: a potential therapeutic target for diverse human diseases. Signal Transduction and Targeted Therapy, May 2021. URL: https://doi.org/10.1038/s41392-021-00567-7, doi:10.1038/s41392-021-00567-7. This article has 311 citations and is from a peer-reviewed journal.
38. (borgo2021proteinkinaseck2 pages 16-17): Christian Borgo, Claudio D’Amore, Stefania Sarno, Mauro Salvi, and Maria Ruzzene. Protein kinase ck2: a potential therapeutic target for diverse human diseases. Signal Transduction and Targeted Therapy, May 2021. URL: https://doi.org/10.1038/s41392-021-00567-7, doi:10.1038/s41392-021-00567-7. This article has 311 citations and is from a peer-reviewed journal.
39. (cao2014identificationofa pages 13-13): Jennifer Yinuo Cao, Kathy Shire, Cameron Landry, Gerald D. Gish, Tony Pawson, and Lori Frappier. Identification of a novel protein interaction motif in the regulatory subunit of casein kinase 2. Molecular and Cellular Biology, 34:246-258, Jan 2014. URL: https://doi.org/10.1128/mcb.00968-13, doi:10.1128/mcb.00968-13. This article has 32 citations and is from a domain leading peer-reviewed journal.
40. (choi2024caseinkinase2 pages 23-25): Yeseul Choi, Seong-Ryong Yu, Yujin Lee, Ann-Yae Na, Sangkyu Lee, Joseph Heitman, Ran Seo, Han-Seung Lee, Jong-Seung Lee, and Yong-Sun Bahn. Casein kinase 2 complex: a central regulator of multiple pathobiological signaling pathways in cryptococcus neoformans. mBio, Feb 2024. URL: https://doi.org/10.1128/mbio.03275-23, doi:10.1128/mbio.03275-23. This article has 2 citations and is from a domain leading peer-reviewed journal.
41. (cozza2010howdruggableis pages 37-39): Giorgio Cozza, Andrea Bortolato, and Stefano Moro. How druggable is protein kinase ck2? Medicinal Research Reviews, May 2010. URL: https://doi.org/10.1002/med.20164, doi:10.1002/med.20164. This article has 85 citations and is from a domain leading peer-reviewed journal.
42. (cozza2013kinaseck2inhibition pages 17-18): G. Cozza, L. Pinna, and S. Moro. Kinase ck2 inhibition: an update. Current Medicinal Chemistry, 20:671-693, Jan 2013. URL: https://doi.org/10.2174/092986713804999312, doi:10.2174/092986713804999312. This article has 110 citations and is from a peer-reviewed journal.
43. (cozza2016caseinkinasesas pages 16-17): Giorgio Cozza and Lorenzo A Pinna. Casein kinases as potential therapeutic targets. Expert Opinion on Therapeutic Targets, 20:319-340, Mar 2016. URL: https://doi.org/10.1517/14728222.2016.1091883, doi:10.1517/14728222.2016.1091883. This article has 103 citations and is from a peer-reviewed journal.
44. (gowda2017caseinkinaseii pages 1-3): Chandrika Gowda, Mario Soliman, Malika Kapadia, Yali Ding, Kimberly Payne, and Sinisa Dovat. Casein kinase ii (ck2), glycogen synthase kinase-3 (gsk-3) and ikaros mediated regulation of leukemia. Advances in Biological Regulation, 65:16-25, Aug 2017. URL: https://doi.org/10.1016/j.jbior.2017.06.001, doi:10.1016/j.jbior.2017.06.001. This article has 28 citations and is from a peer-reviewed journal.
45. (issinger2009proteinkinaseck2 pages 12-16): OG Issinger K Niefind, J Raaf. Protein kinase ck2 in health and disease. Cellular and Molecular Life Sciences, 66:1800-1816, Apr 2009. URL: https://doi.org/10.1007/s00018-009-9149-8, doi:10.1007/s00018-009-9149-8. This article has 134 citations and is from a domain leading peer-reviewed journal.
46. (litchfield2003proteinkinaseck2 pages 2-3): David W. LITCHFIELD. Protein kinase ck2: structure, regulation and role in cellular decisions of life and death. Biochemical Journal, 369:1-15, Jan 2003. URL: https://doi.org/10.1042/bj20021469, doi:10.1042/bj20021469. This article has 1572 citations and is from a domain leading peer-reviewed journal.
47. (litchfield2003proteinkinaseck2 pages 5-6): David W. LITCHFIELD. Protein kinase ck2: structure, regulation and role in cellular decisions of life and death. Biochemical Journal, 369:1-15, Jan 2003. URL: https://doi.org/10.1042/bj20021469, doi:10.1042/bj20021469. This article has 1572 citations and is from a domain leading peer-reviewed journal.
48. (perez2011proteinkinasesck1 pages 1-3): Daniel I. Perez, Carmen Gil, and Ana Martinez. Protein kinases ck1 and ck2 as new targets for neurodegenerative diseases. Medicinal Research Reviews, Nov 2011. URL: https://doi.org/10.1002/med.20207, doi:10.1002/med.20207. This article has 199 citations and is from a domain leading peer-reviewed journal.
49. (prudent2010structurebaseddiscoveryof pages 6-6): Renaud Prudent, Céline F. Sautel, and Claude Cochet. Structure-based discovery of small molecules targeting different surfaces of protein-kinase ck2. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1804:493-498, Mar 2010. URL: https://doi.org/10.1016/j.bbapap.2009.09.003, doi:10.1016/j.bbapap.2009.09.003. This article has 67 citations.
50. (venerando2022editorialcaseinkinases pages 1-3): Andrea Venerando, Victor H. Bustos, Lorenzo A. Pinna, and Giorgio Cozza. Editorial: casein kinases in human diseases. Frontiers in Molecular Biosciences, Dec 2022. URL: https://doi.org/10.3389/fmolb.2022.1094922, doi:10.3389/fmolb.2022.1094922. This article has 2 citations and is from a peer-reviewed journal.